PharmaVoice reports that merger, acquisition, and IPO activity are rebounding as drugmakers race to replace revenue lost to patent expirations. Findley Gillespie, principal at Baker Tilly, said many firms remain ill-prepared for the fast transition from early deal talks to full diligence. Speed and investor confidence are now critical. Companies that can’t produce clean financials, current audits, or clear capitalization tables risk losing both buyers and value. Gillespie cited one firm whose missing cap table delayed a deal by six months, a setback that echoed across its investor base. He also warned that even funding sources like special purpose acquisition companies face hard deadlines, typically 18 to 24 months after their own IPOs. On the scientific side, he noted, unclear intellectual property or weak commercialization narratives can derail negotiations midstream, sometimes abruptly.
The analyst read is that 2026’s deal rebound will reward operational discipline over opportunism. Investors are again deploying capital, yet due diligence standards have only tightened. The practical takeaway for pharma executives: “deal readiness” now begins well before any approach from a buyer. Accurate financial reporting, maintained equity records, and defensible IP positions are prerequisites, not afterthoughts. The next wave of consolidation may favor midsize biotechs that have invested in governance and compliance infrastructure; they can move quickly once inbound interest materializes. Watch for private companies that recently updated audits or refreshed IP filings. They’re signaling to potential acquirers that they’re ready to transact, quickly, and with confidence.
